What kind of drug is mivamutide? How does it work in cancer treatment?

Mifamurtide (Mifamurtide) is an immunotherapy drug mainly used to treat osteosarcoma, especially patients with high-risk recurrent osteosarcoma. It is an immunomodulator that enhances the body's anti-tumor response by activating the immune system. The mechanism of action of mivamutin is not only limited to directly inhibiting the proliferation of tumor cells, but also promoting the body's own immune system to recognize and attack tumor cells by enhancing the function of monocytes and macrophages.

Mivamut peptide enhances the anti-tumor ability of the immune system by activating the immune response of T cells and natural killer cells (NK cells). Especially in the treatment of osteosarcoma, mivamutide can further stimulate the effects of other cells in the immune system by promoting the secretion of cytokines by macrophages. Its mechanism of action is different from traditional chemotherapy drugs. Miavamutin does not directly kill tumor cells, but fights tumors by regulating the patient's own immune response.

The therapeutic effect of miavamuttide has been confirmed in clinical studies, especially when used in combination after surgery, it can significantly reduce the risk of osteosarcoma recurrence. It is often used in combination with chemotherapy drugs to help patients reduce the chance of cancer cells returning after regular chemotherapy. By combining with chemotherapy drugs, mivamut not only improves the therapeutic effect, but also enhances the patient's immune tolerance to a certain extent and reduces the occurrence of side effects.

Although mivamutide has shown good efficacy in the treatment of osteosarcoma, its use is also accompanied by certain immune reactions and side effects, including fever, chills, muscle pain, etc. In order to maximize the therapeutic effect and reduce adverse reactions, doctors usually develop individualized treatment plans based on the patient's specific conditions and conduct regular monitoring of the patient to ensure the safety and effectiveness of the treatment process.

xa0

References: https://pubmed.ncbi.nlm.nih.gov/23997016/